I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Feldman, T.
1816
results:
Articles (Online) X
Search for persons
X
Languages
english (1775)
italian (1)
Sorted by: Relevance
Sorted by: Year
?
1
Variation Of Coronary Atherosclerosis Across Spectrum Of In..:
Nasir, K.
;
Lahan, S.
;
Maqsood, M.
...
Journal of Cardiovascular Computed Tomography. 17 (2023) 4 - p. S41-S42 , 2023
Link:
https://doi.org/10.1016/..
?
2
Encouraging complete responses (CRs) with CDK9 inhibitor AZ..:
Zinzani, P. L.
;
Feldman, T.
;
Collins, G.
...
Hematological Oncology. 41 (2023) S2 - p. 568-569 , 2023
Link:
https://doi.org/10.1002/..
?
3
PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DA..:
Torka, P.
;
Feldman, T.
;
Savage, K.
...
Hematological Oncology. 41 (2023) S2 - p. 161-162 , 2023
Link:
https://doi.org/10.1002/..
?
4
Evaluation of ctDNA in a phase I/II trial in relapsed or re..:
Soong, D.
;
Thieblemont, C.
;
Karavitis, J.
...
Hematological Oncology. 41 (2023) S2 - p. 326-328 , 2023
Link:
https://doi.org/10.1002/..
?
5
Phase 1 trial of KT‐333, a STAT3 degrader, in patients with..:
Smith, S.
;
Olszewski, A.
;
Starodub, A. N.
...
Hematological Oncology. 41 (2023) S2 - p. 567-568 , 2023
Link:
https://doi.org/10.1002/..
?
6
P‐BT‐23 | The Impact of Cryopreservation Media on the Funct..:
Tatari‐Calderone, Z.
;
Awatefe, H.
;
Feldman, T.
.
Transfusion. 63 (2023) S5 - p. , 2023
Link:
https://doi.org/10.1111/..
?
7
PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblas..:
Moskowitz, A.
;
Savage, K.
;
Feldman, T.
...
Hematological Oncology. 41 (2023) S2 - p. 351-353 , 2023
Link:
https://doi.org/10.1002/..
?
8
SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REM..:
Thieblemont, C.
;
Karimi, Y.
;
Jurczak, W.
...
Hematological Oncology. 41 (2023) S2 - p. 142-144 , 2023
Link:
https://doi.org/10.1002/..
?
9
OA1‐AM23‐MN‐12 | Evaluation of Novel Biochemical Tags as Al..:
Feldman, T.
;
Tatari‐Calderone, Z.
;
Brown, B.
Transfusion. 63 (2023) S5 - p. , 2023
Link:
https://doi.org/10.1111/..
?
10
LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE..:
Nastoupil, L. J.
;
Kamdar, M.
;
Chavez, J. C.
...
Hematological Oncology. 41 (2023) S2 - p. 212-214 , 2023
Link:
https://doi.org/10.1002/..
?
11
LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCY..:
Siddiqi, T.
;
Maloney, D. G.
;
Kenderian, S. S.
...
Hematological Oncology. 41 (2023) S2 - p. 60-62 , 2023
Link:
https://doi.org/10.1002/..
?
12
Sexual problems in MS: Sex differences and their impact on ..:
Kaplan, T.B.
;
Feldman, T.
;
Healey, B.
...
Multiple Sclerosis and Related Disorders. 74 (2023) - p. 104672 , 2023
Link:
https://doi.org/10.1016/..
?
13
Prevalence of Non-Hodgkin Lymphoma Patients at High Risk of..:
Danish, A.
;
Della Pia, A.
;
Varughese, T.
...
International Journal of Radiation Oncology*Biology*Physics. 117 (2023) 2 - p. e463-e464 , 2023
Link:
https://doi.org/10.1016/..
?
14
S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN..:
Carlo-Stella, C.
;
Ansell, S.
;
Zinzani, P. L
...
HemaSphere. 6 (2022) - p. 102-103 , 2022
Link:
https://doi.org/10.1097/..
?
15
P1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DAC..:
Lee, H.
;
Flinn, I. W.
;
Melear, J.
...
HemaSphere. 6 (2022) - p. 979-980 , 2022
Link:
https://doi.org/10.1097/..
1-15